MedDRA preferred term · low blood magnesium

Hypomagnesaemia: adverse event reports recording this term

13,671 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

13,671
reports recording the term: 0.1% of all reports; 975
reports, 12 months to June 2026: 1,018 in the 12 months before; 96.8%
marked serious by the reporter: 57.4% across all reports; 7.4%
record death among outcomes, as reported: 9.1% across all reports

13,671 reports in FDA's adverse event database record the MedDRA term "Hypomagnesaemia" (in plain words, low blood magnesium): 0.1% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

975 reports recorded it in the 12 months to June 2026, close to the 1,018 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 96.8% are marked serious, 7.4% include death among the outcomes and 69.6% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Omeprazole, Pantoprazole and Carboplatin. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Omeprazole	Proton pump inhibitor	2,256	3.7%
Pantoprazole	Proton pump inhibitor	1,134	2.5%
Carboplatin	Platinum-based drug	754	0.7%
Cisplatin	Platinum-based drug	658	1%
Furosemide	Loop diuretic	579	1.2%
Lansoprazole	Proton pump inhibitor	567	2.1%
Esomeprazole	Proton pump inhibitor	507	2.9%
Vectibix	Epidermal growth factor receptor antagonist	482	5.2%
Fluorouracil	Nucleoside metabolic inhibitor	474	0.8%
Oxaliplatin	Platinum-based drug	414	0.6%
Erbitux	Epidermal growth factor receptor antagonist	341	1.9%
Panitumumab	Epidermal growth factor receptor antagonist	339	6%
Paclitaxel	Microtubule inhibitor	332	0.5%
Metformin	Biguanide	311	0.5%
Bevacizumab	Vascular endothelial growth factor inhibitor	274	0.5%
Cetuximab	Epidermal growth factor receptor antagonist	259	2.4%
Etoposide	Topoisomerase inhibitor	258	0.4%
Hydrochlorothiazide	Thiazide diuretic	258	1.1%
Tacrolimus	Calcineurin inhibitor immunosuppressant	252	0.3%
Cyclophosphamide	Alkylating drug	207	0.1%
Dexamethasone	Corticosteroid	196	0.2%
Amlodipine	Calcium channel blocker	195	0.4%
Irinotecan	—	194	1%
Indapamide	Thiazide-like diuretic	175	3.1%
Pantoprazole sodium	Proton pump inhibitor	174	0.4%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Proton pump inhibitor	5,076	1%	0.6%
Platinum-based drug	1,826	0.8%	0.7%
Epidermal growth factor receptor antagonist	1,421	3.2%	3.8%
Nucleoside metabolic inhibitor	927	0.3%	0.1%
Loop diuretic	703	1%	0.6%
Microtubule inhibitor	519	0.4%	0.2%
Kinase inhibitor	473	0.1%	0%
Corticosteroid	472	0.1%	0%
Biguanide	456	0.4%	0.1%
Programmed death Receptor-1 blocking antibody	427	0.2%	0.2%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.3%45

2 to 111%138

12 to 171%141

18 to 447.2%982

45 to 6425.9%3,536

65 to 7424.1%3,294

75 and over21.6%2,959

Age not given18.8%2,576

Patient sex

Female48.3%6,598

Male40.9%5,593

Not given10.8%1,480

Grey bar: all 20,646,523 reports in the database. 30.5% of these reports give the United States as the country.

Questions about "Hypomagnesaemia"

What does "Hypomagnesaemia" mean in an adverse event report?

In plain language: low blood magnesium. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record hypomagnesaemia?

13,671 reports through June 2026 (0.1% of all reports), 975 of them in the latest 12 months.

Which drugs appear most often in these reports?

Omeprazole (2,256), Pantoprazole (1,134), Carboplatin (754), Cisplatin (658) and Furosemide (579). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.